Lingo is Abbott’s over-the-counter continuous glucose monitor (CGM) for nondiabetic people. Withings users will also be able ...

DexCom overview and recent share performance DexCom (DXCM) has drawn fresh attention as investors reassess its continuous glucose monitoring business and recent share performance, with the stock last ...

This was the stock's second consecutive day of gains.

This is a Class I recall where 56 serious injuries have been reported. If you use one of Dexcom's continuous glucose monitoring systems, here's what you need to know. Taylor Leamey wrote about all ...

DexCom announced that Chairman and CEO Kevin R. Sayer has taken a temporary medical leave as of September 14, 2025, with President and COO Jacob S. Leach appointed interim CEO and Mark Foletta as ...

Apple Watches are more than just feature-packed wearables; they're important tools for monitoring our health, including our heart rate, sleep patterns, and cardio fitness. Even if you don't know every ...

As the United States approaches 2026, key structural shifts in retirement and healthcare financing are poised to affect how ...

In 2022, Dexcom began rolling out in Europe the Dexcom One system, a straightforward continuous glucose monitoring setup that stripped away some of the bells and whistles of its flagship G-series CGMs ...

Oura and Dexcom are partnering on metabolic health — and they mean big business. Dexcom has invested $75 million into Oura to make the deal happen, valuing Oura at $5 billion. That works out to just a ...

We think that DexCom stock (NASDAQ NDAQ: DXCM) is currently a better pick than Insulet stock (NASDAQ: PODD), given DexCom’s DXCM better prospects and comparatively lower valuation. DXCM stock trades ...